Abstract Objective: To determine the use of the prostate specific antigen (PSA) level and digital rectal examination (DRE) findings to estimate the resected tissue weight (RTW) before transurethral resection of the prostate (TURP).
RTW, resected tissue weight; PV, prostate volume (P < 0.001), respectively. Similarly, the median (range) RTW was 11 (6-59) vs. 26.2 (6-60) vs. 42 (7-60) g in small vs. moderate vs. large prostates (DREb) (P < 0.001), respectively. Using PSA level and DREb (model 3) there was a significantly better ability to estimate RTW than using PSA and DREa (model 2) or PSA alone (model 1) based on ROC curve analyses. The equation developed by model 3 (RTW = 1.2 + (1.13 · PSA) + (DREb · 9.5)) had a sensitivity and specificity of 82% and 71% for estimating a RTW of >30 g, and 84% and 63% for estimating a RTW of >40 g, respectively.
Conclusions: The PSA level and DRE findings can be used to predict the RTW before TURP. ª 2014 Arab Association of Urology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/3.0/).
Introduction
Although new technologies are increasing dramatically TURP continues to be the referent for all procedures treating obstructive LUTS in men. Before surgery an estimation of prostatic volume (PV) is mandatory as it is related to disease progression, unfavourable outcomes, surgical guidance and is a good estimate of the response to surgery [1, 2] . The most reliable method to calculate PV is by TRUS [3, 4] . Nevertheless, there are many concerns about the results of TRUS. It has been shown that the measured PV can vary with the experience of the operator, the size of the prostate and the presence of a third lobe [5, 6] . In addition, conventional bi-dimensional ultrasonography has been shown to be less accurate than three-dimensional ultrasonography [6] . The relationship between PSA level and TRUSmeasured PV was assessed in many previous publications. This strong relationship was confirmed in patients in China [7] , Korea [8, 9] , Taiwan [10] and Netherlands [11] . Even in a large population of patients undergoing screening, PSA levels correlate well with the PV measured by a DRE [12] . In addition, recently the metabolic syndrome and obesity have been shown to influence both PSA levels and PV to a great extent [13] [14] [15] [16] . Therefore, it was suggested that for an accurate estimation of PV, PSA measurements and obesity indices should be included [13, 17] .
TRUS-based measurements of PV have shown a strong correlation with resected tissue weight (RTW) [18, 19] , as during TURP only adenomatous tissue is resected. Although the RTW might not be an indicator of the degree of clinical improvement after TURP [20] , it might be an indicator of further prostatic growth and the need for re-treatment [21, 22] . Furthermore, predicting the RTW might aid adequate surgical planning before surgery. As there are no previous studies that have correlated PSA level or obesity indices with RTW, in the present study we determined the utility of preoperative variables for estimating the RTW before TURP.
Patients and methods
After obtaining internal review board approval, we retrospectively reviewed our electronic databases for patients who underwent surgery for obstructive LUTS related to BPH between December 2006 and December 2011 and who had completed P6 months of follow-up (983 men). Only patients who had a standard monopolar TURP were included. Patients were excluded if they had undergone any surgical procedure other than TURP (37) and those with missing data for PSA or RTW (207). For the purpose of obtaining an homogenous data distribution, patients with a PSA level of >20 ng/mL (31) and a RTW of >60 (18) were also excluded. All patients with a preoperative PSA level of >4 ng/mL had biopsy-confirmed BPH before surgery.
For each patient the electronic database was reviewed for their demographics, including, age, presentation, associated medical comorbidity and BMI. Each patient had a DRE before TURP, carried out by the surgeon. The approximate size of the prostate was reported as 'mild enlargement' if the size was the same as the distal phalanx of the index finger, 'marked' if the boundaries could not be felt digitally, and 'moderate' for any other sizes. Preoperative laboratory investigations included measurements of the preoperative total PSA, serum creatinine and haemoglobin levels. A flow curve and postvoid residual urine volume were routinely assessed before surgery. The TRUS-measured PV was not routinely obtained in every patient.
All patients underwent a standard monopolar TURP, with documented resection of most of the adenomatous tissue. Patients with documented tunnelling only or with incomplete removal of the adenoma were excluded. After resection the removed adenomatous tissue was compressed and immediately weighed before being examined histopathologically. Patients were maintained on quinolone antibiotics for 2 weeks after removal of the urethral catheter. To confirm any clinical improvement, all patients had their postvoid residual estimated and a flow curve assessed at least once during the follow-up.
The primary outcome was the RTW that was associated with alleviating obstructive LUTS and that was not associated with further prostatic re-intervention at least within the 6 months after surgery. Therefore, any patients requiring re-intervention for residual adenoma within the next 6 months were excluded (seven).
Statistical analysis
The correlation between age, serum PSA level, BMI and RTW was investigated using the Pearson correlation coefficient. The median RTW was compared between subcategories of DREa and DREb using the MannWhitney U-test and Kruskal-Wallis test, respectively. Variables showing a significant correlation with RTW were entered into a linear regression model to construct an equation to estimate the RTW. As the DRE was reported to be associated accurately with large prostates of >50 g [23] , the DRE category was entered twice in two different models together with PSA level, after combining mild and moderate prostates as 'small' vs. 'large' prostates (DREa), and as 'mild, moderate' vs. 'marked enlarged' prostates (DREb). The predicted values of the derived equations were compared with the actual values of RTW at different thresholds using the receiver operating characteristic (ROC) curve.
Results
In all, 693 patients met the study inclusion criteria within the specified period. The patients' demographics are shown in Table 1 . The RTW showed no correlation with age (r = 0.07, P = 0.05) or BMI (r = 0.07, P = 0.04), but there was a moderately positive significant correlation with PSA level (r = 0.4, P < 0.001). The median (range) RTW was significantly higher in patients with large vs. small prostates (DREa), at 45 (7-60) g vs. 15 (6-60) g, respectively (P < 0.001). Similarly, the median RTW differed significantly between small vs. moderate vs. large prostates (DREb), at 11 (6-59) vs. 26.2 (6-60) vs. 42 (7-60) g, respectively (P < 0.001). Therefore, equations to estimate the RTW were developed based on three regression models using preoperative PSA level alone as a predictor (model 1), PSA and DREa (model 2), and PSA and DREb (model 3) as predictors ( Table 2) . Model 1 explained only 16.4% of the variance of RTW values whilst adding DRE findings increased the predictive ability of the model to 29% and 34% for models 2 and 3, respectively.
After constructing ROC curves for the three models ( Fig. 1A and B) , the model 3 equation showed the best predictive ability for a RTW of >30 g, with an area under the curve (AUC) and 95% CI of 0.8 (0.790- 12.7 (4.5) RTW (g) 22 (13) 0.849) (P < 0.001), with a sensitivity of 82% and specificity of 71% at a threshold estimated RTW of >23.5 g. On comparing the three models, the difference between the areas of model 1 and 2 (95% CI) was 0.036 (0.013-0.058) (P = 0.001), and the difference between models 2 and 3 (95% CI) was 0.064 (0.04-0.089) (P < 0.001). Similarly, the model 3 equation had significantly the best predictive ability when compared to models 1 and 2 for estimating a RTW of >40 g, with an AUC of 0.8 (0.771-0.832) (P < 0.001), with a sensitivity of 84% and specificity of 63% at the same threshold value. On comparing models 1 and 2, the difference (95% CI) between areas was 0.071 (0.028-0.114) (P = 0.001), and the difference in areas between models 2 and 3 was 0.029 (À0.003-0.062) (P = 0.08). Table 3 shows the results of the ROC curves.
Discussion
The RTW and not the total PV is the actual determinant of operating time and consequently it is directly related to the perioperative complication rates [24] . Therefore, predicting the RTW might be important in surgical planning before TURP. In the present study there was a moderately significant positive correlation between the preoperative serum PSA level and DRE, and the RTW after TURP, whilst age and BMI had very weak correlations. In addition, adding the DREb gave a significantly better performance of the model for estimating the RTW than using PSA alone or PSA and DREa as predictors.
The relationship between age, total PSA level, obesity indices and TRUS-measured PV was reported previously [14, 25] . Nevertheless, age and BMI were weakly correlated with RTW in the present study. During TURP only obstructing adenomatous tissue is removed, with sparing of the peripheral and prostatic capsular tissues. Therefore, this eliminates to a major extent the effect of age and BMI on PV. Furthermore, as the RTW is not necessarily correlated with PV, the expected effect of age and BMI is reduced.
Although a preoperative estimation of PV is essential, there is a debate as to whether the total PV is an indicator of how much tissue should be resected during TURP. Park et al. [21] compared 85 patients with a mean PV of 59.7 g and mean RTW of 11.2 g vs. 178 with a mean PV of 69.9 g and mean RTW of 24 g. Hakenberg et al. [20] reported 138 men who underwent TURP, in whom the mean PV was 49 g and the mean RTW was 24.7 g. However, the RTW was shown to correlate significantly with transitional zone volume as measured by TRUS. Aus et al. [24] reported a significant positive correlation between the RTW and transitional zone volume before and after TURP. In another report, Alkan Figure 1 ROC curves for the three models for (A), estimating a RTW of >30 g, and (B), of >40 g. et al. [19] described a strong correlation between the estimated and resected volumes. Milonas et al. [18] compared the RTW of adenomas removed by TURP and open prostatectomy with corresponding TRUS measurements, found a strong correlation between adenomas enucleated during open prostatectomy, with a weak correlation with adenomas removed by TURP.
Another issue to be addressed is how much RTW is needed to achieve a clinical improvement. Hakenberg et al. [20] correlated the RTW with the clinical outcome as measured by symptom scores after TURP, and found that the RTW was negatively correlated with symptom scores, and that there was no significant correlation between the ratio of RTW to PV and the change in symptom scores. The authors declared that early symptomatic improvement was dependent on the RTW, but the relationship was weak because of possible other confounding variables. They also admitted that the completeness of resection is not mandatory for the optimum clinical outcome. Park et al. [21] compared the outcome between patients who had a RTW ratio of >50% and <50%, and found no statistically significant difference in the clinical outcome even after stratification according to PV. Those authors suggested that a complete resection might not be mandatory for an optimal clinical improvement. Furthermore, a limited resection might be enough for patients with larger prostates.
The DRE has been shown to predict large prostates (>50 g) [23] . In the present study our routine daily practice was used to define the DRE findings regarding the PV in the context of BPH. Although subjective our definition of prostatic enlargement depends on extreme values to minimise the bias between surgeons. All our reported findings were the records of the senior surgeon operating on the patient. In addition, the very large prostate and the very small were defined first and then any size in between was deemed 'moderate'. Two models were used that included the DRE finding, one assessed by 'small vs. large' prostates to minimise the bias if the three-level classification was used. Model 3 including a DRE defined as 'mild vs. moderate vs. marked' enlargement and showed the largest AUC and the best ability to discriminate a RTW of >30 g and >40 g.
The present study has several limitations; first, the outcome defined as the RTW is not consistent across different patients and mainly depends on surgeon volume, as some surgeons prefer to resect the whole adenoma and others do not. Nevertheless, our general policy is to resect the whole adenomatous tissue up to the capsule. Second, the definition of DRE findings is subjective, but our policy to depend on extreme observations might minimise any bias related to the DRE measurement. Third, the study was retrospective and thus had all the limitations related to this design. Fourth, we had no internal validation arm for the provided equations and hence further validation is required. Finally, our equation did not account for surgeon volume, as an experienced surgeon can resect more tissue than a trainee. Nevertheless, the study described the experience of TURP over a 6-year period and therefore it was difficult to assess the accurate volume for each surgeon.
However, to the best of our knowledge this is the first reported study to correlate the RTW with preoperative variables. We believe that the findings of the current study might be beneficial in clinical practice to allow an approximate estimate of the RTW before TURP, and therefore aid better surgical planning for optimising the outcome of the procedure.
In conclusion, the RTW can be predicted from PSA level before TURP, and this prediction is improved after adding the finding of a DRE. These equations could be used for better surgical planning before TURP. Further studies are needed to validate these findings.
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